Updated analyses from 3 phase III trials continue to support Opdivo and its combinations for NSCLC

U.S. government shuts down
Impact on NCI uncertain as administration threatens more RIFs

On Oct. 1, for the first time in six years, the U.S. government shut down after Congress was unable to reach a deal to fund federal agencies for Fiscal Year 2026.

October 03, 2025

Vol.51 No.36

By Claire Marie Porter

Obituary

Harvey Golomb, past chair of UChicago’s Department of Medicine, dies at 82
Golomb was a translational scientist (before that term was in vogue)

It is with profound sadness that I announce the passing of our esteemed colleague and friend, Dr. Harvey Golomb. He died on Aug. 20.

Rybrevant + Lazcluze block resistance, extend survival in first-line EGFR-mutated NSCLC, phase III trial shows

Rybrevant (amivantamab-vmjw) + Lazcluze (lazertinib) demonstrated a statistically significant and clinically meaningful overall survival improvement for patients with previously untreated locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or L858R substitution mutations, according to data from the phase III Mariposa study.

September 12, 2025

Vol.51 No.33

Clinical Roundup

NeXT Personal MRD test predicts NSCLC outcomes, phase III trial shows

NeXT Personal, a highly sensitive molecular residual disease test, is a strong predictor of outcomes in patients with stage II-IIIb, EGFR-mutated non-small cell lung cancer receiving neoadjuvant therapy, according to data from NeoADAURA phase III clinical trial run by AstraZeneca.

September 12, 2025

Vol.51 No.33

In Brief

Richard Schilsky to leave role as PI of ASCO’s TAPUR study

Richard L. Schilsky will be leaving his role as inaugural principal investigator of the American Society of Clinical Oncology-led Targeted Agent and Profiling Utilization Registry study after a decade of leadership.

September 05, 2025

Vol.51 No.32

In Brief

CancerLinQ receives ASCO-certified RQS status

Concert AI’s CancerLinQ initiative has received ASCO’s Recognized Quality Solution status—a recognition that positions the platform as a validated gateway for partnered oncology practices into ASCO’s flagship certification program.

September 05, 2025

Vol.51 No.32

Updated analyses from 3 phase III trials continue to support Opdivo and its combinations for NSCLC

YOU MAY BE INTERESTED IN

U.S. government shuts down
Impact on NCI uncertain as administration threatens more RIFs

Harvey Golomb, past chair of UChicago’s Department of Medicine, dies at 82
Golomb was a translational scientist (before that term was in vogue)

Rybrevant + Lazcluze block resistance, extend survival in first-line EGFR-mutated NSCLC, phase III trial shows

NeXT Personal MRD test predicts NSCLC outcomes, phase III trial shows

Richard Schilsky to leave role as PI of ASCO’s TAPUR study

CancerLinQ receives ASCO-certified RQS status

Renew today!

Subscriber content

Never miss an issue!

Login

Updated analyses from 3 phase III trials continue to support Opdivo and its combinations for NSCLC

YOU MAY BE INTERESTED IN

U.S. government shuts downImpact on NCI uncertain as administration threatens more RIFs

Harvey Golomb, past chair of UChicago’s Department of Medicine, dies at 82Golomb was a translational scientist (before that term was in vogue)

Rybrevant + Lazcluze block resistance, extend survival in first-line EGFR-mutated NSCLC, phase III trial shows

NeXT Personal MRD test predicts NSCLC outcomes, phase III trial shows

Richard Schilsky to leave role as PI of ASCO’s TAPUR study

CancerLinQ receives ASCO-certified RQS status

Never miss an issue!

Login

U.S. government shuts down
Impact on NCI uncertain as administration threatens more RIFs

Harvey Golomb, past chair of UChicago’s Department of Medicine, dies at 82
Golomb was a translational scientist (before that term was in vogue)